THERAPY DOSSIER · th-6847f516054e

Tumour necrosis factor alpha

Biologic · Tumour necrosis factor alpha (TNF-alpha) used as an exogenous cytokine agent; not resolved to a single therapeutic ChEMBL entry

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Tumour necrosis factor alpha (TNF-alpha) used as an exogenous cytokine agent; not resolved to a single therapeutic ChEMBL entry
Target: Not recorded
Injury models: Crush
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25407441 ↗2014Mixed findings

Tumor necrosis factor alpha has an early protective effect on retinal ganglion cells after optic nerve crush.

MouseCrushPeripheral-nerve crushC57BL/6J wild-type, Tnf-deficient, Bax-deficient and cis-NF-kappaB-EGFP reporter mice on a C57BL/6J backgroundn = At least three retinas per condition for quantitative PCR;…Intraocular (intravitreal) injection2 microlitres of 50 ng or 100 ng intraocularly (results als…5 days before optic nerve crush, or 7 days after crush; TNF alone experiments a…

Model: Optic nerve crush causing retinal ganglion cell death

Tnf-deficient mice lost more ganglion cell layer neurons than wild-type at 14 days (19.46% versus 11.61%) and 21 days (26.55% versus 20.32%), and a single 100 ng TNF injection 5 days before crush reduced retinal ganglion cell loss by almost 50% at 1 week. Injection 7 days after crush had no signifi…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…